Skip to content
Open access

Formulation and Evaluation of Thymoquinone- and Nicotinamide-Loaded Nanostructured Lipid Carriers Combined with Azithromycin Against Staphylococcus aureus and Pseudomonas aeruginosa

Oct 2026 · BioNanoScience · Vol 16 · 0 citations · 23 references

Abstract

Multidrug-resistant (MDR) bacteria pose a significant global health threat, limiting therapeutic options and increasing morbidity, mortality, and healthcare costs. To address this challenge, combinations of natural compounds with existing antibiotics encapsulated in nanostructured lipid carriers (NLCs), are increasingly investigated. Thymoquinone (TQ) and nicotinamide (NIC) are bioactive compounds known for their potent antioxidant and anti-inflammatory properties. This study aimed to formulate and evaluate NLCs co-loaded with TQ and NIC, examining their physicochemical properties and antibacterial activity when combined with the antibiotic azithromycin (AZM) against MDR pathogens. NLCs encapsulating TQ and NIC were prepared via a hot emulsification-ultrasonication technique and characterized using dynamic light scattering (DLS), zeta potential analysis, Fourier-transform infrared spectroscopy (FTIR), encapsulation efficiency (EE%), in vitro drug release assays, and stability studies over two months. Antibacterial efficacy was assessed through agar well-diffusion assays, minimum inhibitory concentration (MIC), and Time-kill assays against standard strains of Staphylococcus aureus and Pseudomonas aeruginosa. The nanostructured lipid carriers (NLCs) were successfully formulated with an average particle size of approximately 200 nm and a low polydispersity index (0.166), indicating a uniform distribution. The moderately negative zeta potential (− 10.6 mV) suggested acceptable colloidal stability. High encapsulation efficiencies were achieved for both active compounds, with thymoquinone (TQ) reaching 91.7% and nicotinamide (NIC) 66.2%. In vitro release studies showed a clear biphasic pattern, characterized by an initial burst release followed by a sustained release phase. TQ exhibited almost complete release within 24 h (~ 95%), whereas NIC demonstrated a slower, more controlled release of approximately 40% over the same period. Stability assessment over two months revealed minimal changes in particle size and surface charge, confirming the formulation’s physical stability. FTIR analysis further confirmed successful encapsulation of both TQ and NIC within the lipid matrix without evidence of chemical degradation or incompatibility. Antibacterial testing demonstrated that the co-loaded NLC formulation combined with azithromycin (AZM) significantly enhanced antibacterial efficacy. The system produced inhibition zones of 48 mm against S. aureus and 35 mm against P. aeruginosa at a reduced AZM concentration (62.5 µg), compared with AZM alone at a higher dose (125 µg), which yielded 40 mm and 38 mm, respectively. MIC results similarly indicated lower inhibitory concentrations for the combination, confirming improved potency. Time-kill assays further supported a strong synergistic effect. The combination induced a rapid and pronounced decline in viable bacterial counts, exceeding AZM alone by more than 2 log units at early time points. This effect was especially evident at higher concentrations, where AZM alone still showed approximately 1.4 × 101 CFU at 8 h, while the combination achieved complete eradication (0 CFU). Overall, these findings highlight the potential of the TQ–NIC co-loaded NLC system as an effective adjuvant to azithromycin for enhanced antibacterial therapy. This study provides promising evidence supporting the use of TQ and NIC encapsulated within NLCs as an effective adjunctive strategy in combating MDR bacterial infections, enhancing the therapeutic efficacy and stability of existing antibiotics.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.